SPY335.84-2.98 -0.88%
DIA279.57-1.46 -0.52%
IXIC10,910.28-140.19 -1.27%

Wedbush Downgrades Sage Therapeutics to Neutral, Raises Price Target of $37

Wedbush analyst Laura Chico downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Neutral and raises the price target from $36 to $37.

Benzinga · 05/08/2020 17:13

Wedbush analyst Laura Chico downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Neutral and raises the price target from $36 to $37.